Belite Bio (BLTE) CFO Chuang Hao-Yuan Sells 67,395 Shares

What Happened
CFO Chuang Hao-Yuan sold a total of 67,395 American depositary shares (ADSs) of Belite Bio (each ADS = 1 ordinary share) in multiple open-market transactions on September 4 and September 8, 2026. The trades were executed at prices ranging roughly from $180.16 to $198.05 per ADS and generated aggregate proceeds of approximately $12,803,530 (about $12.8M). These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2025.

Key Details

• Transaction dates: September 4, 2026 and September 8, 2026.
• Price range: approximately $180.16 to $198.05; overall weighted-average ≈ $190.0 per share (total proceeds ÷ total shares).
• Total sold: 67,395 ADSs for total proceeds ≈ $12,803,530.
• Method/code: Open-market sales (Transaction code S).
• Plan note: Sales were made under a Rule 10b5-1 trading plan adopted 12/22/2025 (footnote F2).
• ADS note: Each ADS represents one ordinary share (footnote F1).
• Footnotes F3–F21: Several footnotes disclose the price ranges and state the reporting person will provide a per-price breakdown on request.
• Shares owned after transaction: Not disclosed in the provided filing extract.
• Filing: Form 4 filed on September 9, 2026 reporting trades through Sept 8; the filing extract provided does not indicate a late filing flag.

Context
These transactions were sales (not purchases or option exercises) and were executed under a pre-established 10b5-1 plan. 10b5-1 plans are commonly used to schedule insider trades in advance and can limit the extent to which a sale is taken as an immediate signal of insider sentiment. For retail investors, purchases tend to be more informative about insider confidence; sales—especially those under 10b5-1 plans—can reflect diversification, taxes, or other prearranged needs rather than a change in view.